Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in ...

Benitec Biopharma Inc. (NASDAQ:BNTC) shares soared 20% on Monday after the biotech company announced positive interim results ...

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis ...

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

Investing.com -- Benitec Biopharma Inc. (NASDAQ:BNTC) stock rose 20% on Monday after the company announced positive interim clinical results for its BB-301 gene therapy treatment and received Fast ...

Benitec Biopharma (BNTC) announces the appointment of Dr. Sharon Mates to the board of directors of the Company, effective November 2, 2025.

Benitec has been granted a Type C meeting with the U.S. Food and Drug Administration ("FDA") in the fourth quarter of 2021 The non-clinical data derived from the evaluation of BB-301 in both the ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Benitec Biopharma ( (BNTC)) has ...

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic ...

Benitec Biopharma Inc. (NASDAQ:BNTC – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings ...

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD ...

Benitec Biopharma Inc. (NASDAQ:BNTC – Free Report) – Equities research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Benitec Biopharma in a research report issued ...